New Strength of Trelegy Ellipta Inhaler Available to Treat Asthma In Canada
According to Health Canada, a new strength of Trelegy Ellipta (200/62.5/25 mcg) manufactured by GSK to treat asthma has been approved for sale in Canada since September 13, 2021.
What is Trelegy Ellipta?
Trelegy Ellipta is an inhalation powder containing a combination of fluticasone, umeclidinium, and vilanterol.
It is the first and only once-daily triple therapy in a single Inhaler for patients aged 18 years and older with COPD or asthma.
Trelegy Ellipta is not used to relieve sudden breathing problems and will not replace a rescue inhaler.
Recommended Dosage for Maintenance Treatment of COPD
COPD is a chronic lung disease that includes chronic bronchitis, emphysema, or both.
Trelegy Ellipta is used to improve symptoms of COPD for better breathing and to reduce the number of flare-ups (the worsening of your COPD symptoms for several days).
The recommended dosage of Trelegy Ellipta for maintenance treatment of COPD is 1 actuation of Trelegy Ellipta 100/62.5/25 mcg once daily by oral inhalation.
Trelegy Ellipta 100/62.5/25 mcg is the only strength indicated for the treatment of COPD.
Recommended Dosage for Maintenance Treatment of Asthma
Trelegy Ellipta is a prescription medicine used long term to prevent and control symptoms of asthma for better breathing and to prevent symptoms such as wheezing.
For patients who do not respond adequately to Trelegy Ellipta 100/62.5/25 mcg once daily, increasing the dose to Trelegy Ellipta 200/62.5/25 mcg once daily may provide additional improvement in asthma control.
The maximum recommended dosage is 1 inhalation of Trelegy Ellipta 200/62.5/25 mcg once daily.
The average retail price is $638 USD for 60 doses Trelegy Ellipta (200/62.5/25 mcg) in the United States.
This new strength inhaler is only $401.5 USD for 60 doses from Canadian pharmacy, such as Jason'sCanadadrugstore.com